Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells.
Serafini M, Dylla SJ, Oki M, Heremans Y, Tolar J, Jiang Y, Buckley SM, Pelacho B, Burns TC, Frommer S, Rossi DJ, Bryder D, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Nelson-Holte M, Fine GC, Weissman IL, Blazar BR, Verfaillie CM. Serafini M, et al. Among authors: oki m. J Exp Med. 2007 Jan 22;204(1):129-39. doi: 10.1084/jem.20061115. Epub 2007 Jan 16. J Exp Med. 2007. PMID: 17227908 Free PMC article.
Multipotent adult progenitor cell isolation and culture procedures.
Breyer A, Estharabadi N, Oki M, Ulloa F, Nelson-Holte M, Lien L, Jiang Y. Breyer A, et al. Among authors: oki m. Exp Hematol. 2006 Nov;34(11):1596-601. doi: 10.1016/j.exphem.2006.07.013. Exp Hematol. 2006. PMID: 17046581 Free article.
A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial).
Takeda M, Ota M, Iwama E, Sugawara S, Shukuya T, Umemura S, Tanaka H, Oki M, Takahama T, Masuda T, Nogami N, Shimokawa M. Takeda M, et al. Among authors: oki m. Clin Lung Cancer. 2024 Dec 9:S1525-7304(24)00267-5. doi: 10.1016/j.cllc.2024.12.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39743377
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209
Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).
Katakami N, Nagata K, Nakakura A, Okamoto T, Kaneda T, Oki M, Watanabe K, Tokito T, Amano Y, Tamiya M, Morita S, Hatachi Y. Katakami N, et al. Among authors: oki m. Jpn J Clin Oncol. 2024 Sep 23:hyae132. doi: 10.1093/jjco/hyae132. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39311098
411 results